Bruce D. Cheson
Cheson, Bruce D., 1946-....
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Cheson, Bruce D.
Cheson, B. D.
VIAF ID: 85858205 (Personal)
Permalink: http://viaf.org/viaf/85858205
Preferred Forms
-
100 0 _
‡a
Bruce D. Cheson
-
200 _ |
‡a
Cheson
‡b
Bruce D.
‡f
1946-....
-
100 1 _
‡a
Cheson, B. D.
-
100 1 _ ‡a Cheson, Bruce D
-
100 1 _
‡a
Cheson, Bruce D.
-
100 1 _ ‡a Cheson, Bruce D. (sparse)
-
100 1 _ ‡a Cheson, Bruce D. ‡d (1946- ).
-
100 1 _
‡a
Cheson, Bruce D.
‡d
1946-
-
100 1 _ ‡a Cheson, Bruce D., ‡d 1946-
-
100 1 0
‡a
Cheson, Bruce D.,
‡d
1946-
-
100 1 _
‡a
Cheson, Bruce D.,
‡d
1946-....
4xx's: Alternate Name Forms (2)
Works
| Title | Sources |
|---|---|
| Basic clin. oncol. (Online) |
|
| Chronic lymphoid leukemias |
|
| Clinical trials. Referral resource. Phase II Ovarian Cancer Trials |
|
| Clinical utility of body fluid analyses |
|
| Cogan's syndrome: A systemic vasculitis |
|
| Cogan's syndrome and Bw 17 revisited. |
|
| Combinations or sequences of targeted agents in CLL: is the whole greater than the sum of its parts (Aristotle, 360 BC)? |
|
| Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia |
|
| Complete response to brentuximab vedotin in a transplant-naïve patient with relapsed CD30-positive nodular lymphocyte-predominant Hodgkin lymphoma. |
|
| Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. |
|
| Current approaches to therapy for indolent non-Hodgkin's lymphoma. |
|
| Current role of FDG PET/CT in lymphoma |
|
| Cutis verticis gyrata: unusual chloromatous disease in acute myelogenous leukemia |
|
| Cytologic evidence for disseminated immunoblastic lymphoma |
|
| Defective binding of the third component of complement |
|
| Defective opsonization in multiple myeloma. |
|
| Deoxycoformycin: an active new drug for indolent lymphomas and hairy cell leukemia |
|
| Descriptive analysis of genetic aberrations and cell of origin in Richter transformation |
|
| Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909 |
|
| Determining the sequence of novel therapies in the treatment of relapsed Hodgkin's lymphoma |
|
| Developmental history: bendamustine yesterday, today, tomorrow |
|
| Differentiating agents in the treatment of human malignancies |
|
| Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy |
|
| Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303 |
|
| Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET |
|
| Emerging treatments for indolent lymphoma. |
|
| Ennui or not ennui, that is the question... |
|
| EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma |
|
| Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era |
|
| Expanding our mission: Clinical Lymphoma, Myeloma & Leukemia |
|
| Extended Follow-up of Patients Treated With Bendamustine for Lymphoid Malignancies |
|
| Favorable outcome of central nervous system toxoplasmosis occurring in a patient with untreated Hodgkin's disease |
|
| FDG-PET for Early Response Assessment in Lymphomas: Part 2-Diffuse Large B-Cell Lymphoma, Use of Quantitative PET Evaluation |
|
| FDG-PET lymphoma demonstration project invitational workshop |
|
| Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies |
|
| Fludarabine phosphate--looking forward |
|
| Future strategies toward the cure of indolent B-cell malignancies: introduction. |
|
| Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. |
|
| Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma |
|
| Genetic abnormalities in CLL: prognostic factors--or their own disease? |
|
| Ghostwriting. |
|
| Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone |
|
| Hematologic malignancies: new developments and future treatments |
|
| Hematology: Rituximab for follicular lymphoma: maintaining an open mind |
|
| Hoffman and Abeloff's hematology - oncology review |
|
| New Chemotherapeutic Agents for Non-Hodgkin’s Lymphomas |
|
| Nucleoside analogs in cancer therapy |
|
| Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group |
|
